<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894231</url>
  </required_header>
  <id_info>
    <org_study_id>IIS071108</org_study_id>
    <nct_id>NCT00894231</nct_id>
  </id_info>
  <brief_title>Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis</brief_title>
  <official_title>Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AAADRS Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AAADRS Clinical Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to noninvasively measure the anti-inflammatory effect of
      levocetirizine after two weeks of treatment in allergic rhinitis subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in objective measure of inflammation nasal NO after LC treatment.</measure>
    <time_frame>two weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in nasal eosinophils, QOL and diary scores after LC treatment.</measure>
    <time_frame>two weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xyzal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levocetirizine (Xyzal)</intervention_name>
    <description>5mg po QD</description>
    <arm_group_label>Xyzal</arm_group_label>
    <other_name>Xyzal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>sugar tablet</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICF signed

          -  Diagnosis of PAR for 6-12 months greater

          -  12 years and older

          -  Decreased nasal NO values at baseline

          -  Compliance and ability to perform maneuvers and responsibilities

        Exclusion Criteria:

          -  Oral or systemic steroids for 60 days prior

          -  Inhaled, nasal, nebulized steroids w/i 4 weeks

          -  Hospitalization or life threatening asthma

          -  Use of nasal or oral antihistamines w/i 4 weeks

          -  Upper or lower airways infection

          -  Direct cigarette smoke exposure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel J Lanz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AAADRS Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AAADRS</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>September 3, 2009</last_update_submitted>
  <last_update_submitted_qc>September 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Miguel J Lanz MD FAAAAI</name_title>
    <organization>AAADRS</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

